



July 2021

Harbour BioMed **Journal**
Investor Relations

02142.HK

HARBOUR
BIOMED



CONTENTS


HBM Overview	01
Company Announcement	02
Company News	03
Academic and Research Summit	04
DED and HBM9036	05
HK BioMed Industry	07
Global Market Overview	08

HBM (02142.HK)


Overview	
Website--Investor Access	https://www.harbourbiomed.com/investor
Market Cap (06/30, Mil HK\$)	7602.11
Total Share Capital (Mil)	767.89
Circulation Stock (Mil)	767.89

In June, the major HK market indices have fluctuated, highest at the beginning of the month while falling to lowest in the middle of the month. The HSI and the HSCI are down 2.2% and 2.6%, respectively. HBM has fluctuated quite a lot with the market – highest at the beginning of June while falling to lowest in the middle of June. The monthly average price is HK \$10.34, up 3.85% from the May average, HK \$9.96.

HBM Stock Performance – June



The Hang Seng Composite Index (HSCI) – June



Company Announcement

The company announced to enter into a collaboration agreement with Dana-Farber Cancer Institute, affiliate of Harvard Medical School to co-develop novel biotherapies in cancer treatment including bispecific antibodies and CAR-T cell products. Bispecific antibodies are expected to extend the possibilities of monoclonal antibody (mAb) therapeutics, and CAR-T cell therapy is an innovative immunotherapy that uses specially altered T-cells to redirect them to target cancer cells.

The company announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in open phase I clinical study. This study will evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 in combination with programmed cell death protein 1 (PD-1) antibody in the treatment of solid tumors.



Company News

01

Yiping Rong, PhD, Head of Discovery, attended the Cell Engager Summit to deliver a keynote speech with an exclusive interview.

02

HBM appointed Amy Que, PhD, as Chief Technology Officer.

03

HBM successfully held the Investor Forum, Highly Effective Innovation Engine Drives Value Creation.

04

The company announced Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC.

05

Harbour BioMed and Dana-Farber Cancer Institute collaborate to advance novel biotherapies for cancer treatment.

06

HBM appointed Mr. Ka Chi Yau as Independent non-executive Director, Ms. Weiwei Chen as non-executive Director and Senior Business Advisor.

07

HBM announced a newly developed bispecific antibody at Antibody Engineering & Therapeutics Conference.

Academic and Research Summit

June 30 - July 1 | Digital Event

Cell Engager Summit

Speaker Interview

Exclusive Speaker Interview



Yiping Rong
Head of Discovery Biology
Harbour Biomed


HARBOUR
BIOMED

The 2021 Cell Engager Summit was held virtually from 6/29–7/1. Yiping Rong, PhD, Head of Discovery was invited to deliver a keynote speech with an exclusive interview, presenting HBM's proprietary immune cell engager technology for developing bispecific antibodies and sharing our latest pipeline updates.

Preclinical Evaluation of HBM7022

HBM7022 is a HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody:

- It includes potent and specific killing of CLDN18.2+ gastric cancer cells
- It triggers little to none cytokine release in vitro cytokine release assays
- The bispecific antibody is easily manufactured and purified



These results support clinical testing of HBM7022 as a potential therapeutic option for patients with CLDN18.2+ gastric cancer

The 2021 Antibody Engineering & Therapeutics (AET) Conference was held virtually from 8-10 June, HBM attended the conference and announced a bispecific antibody, HBM7022, which is developed by our own HBICE™ platform. This antibody is a novel oncology immunotherapy drug, and we have demonstrated its unique mechanism of action and remarkable anti-tumor result.

DED and HBM9036

| Current Treatment and Needs for Dry Eye Disease (DED) in China

The main treatment for DED in China now is artificial tears, which can temporarily lubricate the ocular surface, replenish tears, and relieve dry eyes. Diquafosol sodium eye drops, which launched in 2020 can stimulate tear secretion from exogenous hydration. However, for more severe dry eyes, increasing tears as a treatment can no longer meet the needs. The current drugs for moderate to severe dry eye are mainly anti-inflammatory, mainly glucocorticoids, but glucocorticoids have many side effects, which may cause complications such as hormonal glaucoma and cataracts. Cyclosporine has some problems such as obvious local stimulation and slow acting. Currently, the treatment needs a large number of patients cannot be met, and there is a lack of drug options for patients with moderate to severe dry eye.




Common DED Treatment (please consult a doctor or pharmacist before use)

| Pathogenesis of DED

Dry eye is an auto-inflammatory and immune-mediated disease, which is the destruction of the body's immune tolerance to autoantigens.


The pathogenesis of dry eye is now widely recognized as the activation of autoinflammatory response and increased expression of inflammatory factors under internal and external stress such as dry hypertonicity. These inflammatory factors can cause corneal epithelial damage, tear film instability, and increase in tear film osmotic pressure. Under the action of a variety of possible internal and external factors, the ocular surface will eventually form a vicious circle of high osmotic pressure, inflammation and tear film instability.



DED and HBM9036

| Tanfanercept (HBM9036) Mechanism of Action

HBM9036 is an ophthalmic solution engineered from a TNF- α receptor fragment, and it targets TNF- α , an important inflammatory cytokine that causes DED. TNF- α also plays a pivotal role in the pathogenesis of many other inflammatory diseases such as uveitis, rheumatoid arthritis, and Crohn's disease. In animal models, it can reduce ocular surface inflammation, break the vicious cycle of tear hyperosmolarity – ocular surface inflammation – tear film instability, enhance conjunctival goblet cell density, increase tear volume, and improve symptoms and signs of DED by blocking TNF- α , and controlling DED as a result. HBM9036 has entered into Phase III and completed dosing of the first patient. In the previously completed Phase II trial in China, it showed rapid onset of action, significant improvements in symptoms and signs of the patients in treatment group as placebo. Also, it was very well tolerated with similar comfort level compared to placebo.




June 6 is National Eyewear Day.
Scan QR code to learn more
about Dry Eye Disease (DED).

HK BioMed Industry

Market Overview

In June 2021, the HSCI closes at 4,509.66 last day of the month, down 2.57% from the first day of the month. The HSHCI closes at 8,158.55, up 0.92% from the first day of the month. The CESHKB.CSI closes at 16,384.19, up 2.57% from the first day of the month.

HK Listing BioMed Companies (18A)



Closing Date: 06/30/2021

Note: This chart is scaled on logarithmic axes.

Global Market Overview

Global Market Index			
	Closing Price		
	2021.06.01	2021.06.15	2021.06.30
Dow Jones Industrial	34,575.31	34,299.33	34,502.51
Nasdaq Composite	13,736.48	14,072.86	14,503.95
UK FTSE 100	7,080.46	7,172.48	7,037.47
German DAX	15,567.36	15,729.52	15,531.04
France CAC40	6,489.40	6,639.52	6,507.83

HK Market Index			
	Closing Price		
	2021.06.01	2021.06.15	2021.06.30
Hang Seng	29,468.00	28,638.53	28,827.95
Hang Seng Composite	4,628.59	4,489.80	4,509.66
Hang Seng Tech	8,305.74	7,961.02	8,155.37
HS China Enterprise	10,990.75	10,668.93	10,663.39
Hang Seng Healthcare	8,084.50	7,869.47	8,158.55

Global Economic Data – June			
Country	Related Events	Estimated	Actual
US	Richmond Fed Manufacturing	18	22
Germany	Manufacturing PMI Initial Value	63	64.9
UK	Manufacturing PMI Initial Value	64	64.2
EU	Manufacturing PMI Initial Value	62.1	63.1
Germany	IFO Business Climate	100.7	101.8
UK	GfK Consumer Confidence	-7	-9

- The Euro zone sentiment rose for five consecutive months, hitting six-month high at 117.9 – far above the expected value of 116.5.
- The US Consumer Confidence Index rises to 127.3 in June, highest level since February 2020.
- The initial value of the French Consumer Price Index (CPI) expands to 1.5% year-on-year, reaching the high level in January 2020.
- China's official Manufacturing PMI is 50.9%, slightly higher than the expected value of 50.8%.

HARBOUR B I O M E D



Harbour BioMed is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE™) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.



Harbour BioMed

ir@harbourbiomed.com
www.harbourbiomed.com

linkedin:
<https://www.linkedin.com/company/13244036/admin/>